Every 8-K that Iterum Therapeutics plc (ITRM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ITRM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ITRM filings page.
Iterum Therapeutics plc reports that its ordinary shares will be delisted from Nasdaq after the company withdrew its appeal of a prior Nasdaq delisting determination tied to failing the $1.00 minimum bid price requirement. Trading will be suspended at the opening of business on April 1, 2026, with a Form 25-NSE to remove the shares from listing.
The company has filed a Winding Up Petition in the Irish High Court and is in provisional liquidation. Given limited cash and the ongoing winding up process, Iterum does not expect to file its Form 10-K for the year ended December 31, 2025 or make future SEC filings.
Iterum Therapeutics plc has filed a petition in the Irish High Court to wind up the company, and provisional liquidators from Teneo Restructuring have been appointed pending a court hearing on April 13, 2026. If a winding up order is granted, this will lead to the company’s dissolution.
The petition triggers an event of default on Iterum’s royalty-linked subordinated notes, causing interest to step up to the prime rate plus three percent and allowing holders to sue for payment. Board authority has effectively passed to the provisional liquidators, the CEO and CFO have resigned, Nasdaq trading in the shares is expected to be suspended, and the company warns that shareholders may face a significant or complete loss of their investment.
Iterum Therapeutics plc has requested a hearing with a Nasdaq Hearings Panel after receiving a determination letter stating its shares are scheduled for delisting from The Nasdaq Capital Market for failing to meet the $1.00 minimum bid price requirement. The hearing request temporarily halts suspension and delisting while the process plays out, but the company warns there is no assurance of a favorable outcome or any extension.
The company also does not meet Nasdaq’s $35 million minimum market value of listed securities standard and related shareholders’ equity or net income requirements, and must show the Panel it can regain and sustain compliance by June 9, 2026. Iterum is evaluating corporate, strategic and financial alternatives, including potential asset sales, strategic transactions, or a wind-down. It cautions that, given its limited ability to raise capital, a bankruptcy, liquidation, dissolution or similar outcome is possible, in which shareholders are very unlikely to receive any meaningful return.
Iterum Therapeutics plc reports it has received a Nasdaq delisting determination after ongoing failure to meet the $1.00 minimum bid price requirement. Nasdaq plans to suspend trading of its ordinary shares from March 5, 2026 and subsequently file a Form 25-NSE to complete delisting.
The company also remains out of compliance with Nasdaq’s $35 million minimum market value of listed securities standard and related equity or net income requirements. Iterum is evaluating corporate, strategic and financial alternatives, including a potential wind-down or bankruptcy, where shareholders are described as very unlikely to receive any meaningful return.
Iterum Therapeutics plc reported that shareholders at an extraordinary general meeting did not approve four key proposals: an increase in authorized share capital, expanded director authority to issue securities, an opt-out from pre-emption rights, and a reverse share split consolidating 10–15 shares into one. Each proposal received more votes against than for. The company states that these results restrict its ability to raise additional capital and indicate that its operations, financial condition, and ability to continue as a going concern are likely to be materially and adversely affected. Iterum is evaluating options such as asset or technology sales, strategic transactions, or a wind-down, and notes that in a bankruptcy, liquidation, dissolution or similar outcome, shareholders would be very unlikely to receive any meaningful return.
Iterum Therapeutics plc has received a notice from Nasdaq that it no longer meets the Nasdaq Capital Market’s continued listing standards for market value and certain financial criteria. On December 11, 2025, Nasdaq stated that Iterum’s Market Value of Listed Securities had stayed below $35 million for 30 consecutive business days, violating Listing Rule 5550(b)(2), and that the company also fails the alternative shareholder equity and net income requirements.
Iterum has 180 calendar days, until June 9, 2026, to restore its market value to at least $35 million for a minimum of 10 consecutive business days or face potential delisting, with a right to appeal. The company also remains out of compliance with Nasdaq’s $1.00 minimum bid price rule after a prior August 25, 2025 notice and has until February 23, 2026 to achieve a closing bid of at least $1.00 for 10 consecutive business days, with a possible additional 180‑day period if it meets other listing standards. Iterum’s shares continue to trade on Nasdaq for now while it works to regain compliance.
Iterum Therapeutics plc filed a Form 8-K announcing it has furnished a press release with its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information is being furnished—not deemed “filed” under Section 18 of the Exchange Act—and will not be incorporated by reference into other SEC filings. The filing is administrative in nature and includes the Inline XBRL cover page as Exhibit 104.
Iterum Therapeutics (ITRM) filed a prospectus supplement to sell ordinary shares from time to time under its existing at‑the‑market program, targeting additional aggregate gross proceeds of up to $20,000,000, not to exceed 21,756,057 shares, through H.C. Wainwright & Co. as sales agent.
The company previously sold approximately $36.2 million of shares under the same Sales Agreement and earlier prospectuses. Iterum also noted it commercially launched ORLYNVAH™ in the U.S. community market in August 2025 and expects modest sales in 2025 during the early commercialization phase.
Iterum Therapeutics plc reported the results of its 2025 annual general meeting. Shareholders elected David Kelly as a Class I director, with 10,795,342 votes for, 2,848,953 against and 665,812 abstentions, and ratified KPMG as independent registered public accounting firm for the fiscal year ended December 31, 2025, with 17,986,081 votes for and 3,759,990 against.
However, shareholders did not approve several key proposals. The advisory vote on executive compensation failed, with 5,406,944 votes for and 8,449,597 against. Proposals to increase authorized share capital, grant updated authority to allot and issue securities, opt out of pre-emption rights under Irish law, and add 4,000,000 shares to the equity incentive plan were all rejected by wide margins, limiting the board’s flexibility to issue new shares or expand equity-based compensation.
Iterum Therapeutics plc reported receiving a Nasdaq notice on August 25, 2025 stating that its ordinary shares no longer meet the exchange’s minimum bid price requirement. The company fell out of compliance with Nasdaq Listing Rule 5550(a)(2), which requires a closing bid price of at least $1.00 per share based on the last 30 consecutive business days.
The notice does not immediately remove Iterum’s shares from The Nasdaq Capital Market. The company has 180 calendar days, until February 23, 2026, for its closing bid price to reach at least $1.00 for a minimum of 10 consecutive business days to regain compliance. If it fails to do so, Iterum may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially including a reverse share split.
Nasdaq could ultimately move to delist the shares if compliance is not restored, though Iterum could appeal any such decision. The company plans to monitor its share price and consider available options but acknowledges there is no assurance it will regain compliance or avoid delisting.
Iterum Therapeutics plc has begun the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The drug is intended to treat adult women with uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis who have limited or no alternative oral antibacterial options. The launch marks Iterum’s move from development to commercial availability for this product in the United States.